The operation strengthens the clinical and perinatal genetics ecosystem and consolidates the resilience of the innovative fabric housed in the hub.
In a new milestone for the SID/Barcelona community, Veritas Genetics has acquired qGenomics, a company of reference in carrier screening, The integration places qGenomics on a global platform with increased R&D, production and clinical deployment capabilities. The integration places qGenomics on a global platform with greater R&D, production and clinical deployment capabilities, and reinforces the positioning of SID/Barcelona as a strategic node for genomic medicine in Europe.
With this operation, Veritas expands its offering in perinatal and clinical genetics and boosts the company's own development of carrier screening, The new product portfolio completes a comprehensive portfolio for healthcare professionals and patients across all stages of life. For qGenomics, the backing of Veritas consolidates its scientific trajectory and accelerates the transfer of knowledge to the healthcare system.
The success of qGenomics is also excellent news for SID as the operator of SID/Barcelona: having more resilient clients with greater international traction proves the value of an environment that combines ready-to-operate infrastructure, comprehensive services and a connected scientific community. Corporate transactions of this calibre underline the role of SID/Barcelona as a growth catalyst for companies. deeptech and biotech that need to climb without friction.
The combined capabilities of Veritas and qGenomics accelerate the diagnosis of rare diseases and chromosomal disorders, and strengthen the perinatal offering with technologies such as microarrays and carrier screening. As announced by Veritas, the integration also paves the way for the launch of its own carrier screening, marketed as qCarrier, during 2025, consolidating a more comprehensive and accessible clinical approach.
Founded in 2008 as spin-off of the Centre de Regulació Genòmica (CRG) and the Universitat Pompeu Fabra (UPF) by Lluís Armengol, Xavier Estivill and Luis Pérez Jurado, qGenomics has been a technological benchmark for more than 15 years, with the support of investors in the clinical field such as Grupo Dexeus Mujer and Laboratorio Echevarne. Following the transaction, its founding partners and investors have reinvested in Paulus Holdings, a vehicle of Veritas Genetics, and Lluís Armengol has joined the group as Chief Scientific Officer, reinforcing the company's scientific leadership.
The acquisition also continues Veritas' integration strategy in the Iberian market following the acquisition of NIMGenetics in December 2024, creating a unified ecosystem of clinical genetics services under a single brand.
